Many investigators believe that age is just a number and that in fit elderly patients without significant comorbidities, therapies similar to those commonly recommended for younger individuals can be employed. In this regard, we inquired about the use of bevacizumab and found that although Dr Wakelee and most survey respondents don’t have an age cutoff, 
Dr Ramalingam and 28% of oncologists will pull back from using the drug in patients around age 75 to 80. A post-hoc analysis of data from PointBreak and ECOG-E4599 demonstrated that bevacizumab was well tolerated in patients older than age 65, but in those older than 75 more complications were seen.

Langer CJ et al. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. Proc ASCO 2013;Abstract 8073.

Ramalingam SS et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26(1):60-5. Abstract

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract